Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.
about
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesDPP4 in DiabetesSecular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013.Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor.Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
P2860
Q26785454-F460D202-5AA1-4819-8833-794E4D5D02F2Q26797335-83847538-2844-4D7C-B04E-6E971CB32914Q37233958-33D9FD16-B11E-4A5F-AF63-17DD4FFF74EBQ38650405-87DC3CAB-9598-4573-B2D8-6C6F9A9E6F08Q41451154-E7CD9E04-ADF9-46B5-9FAD-3E4BB3A3FC18Q41811814-80CE68A8-3DBE-4979-8CF0-D9CA5AA01210Q43163467-08A4FDD4-EE3F-42BE-8F9C-4726D8953C60Q47185104-7BE863B7-F551-45AE-A761-78134B9A0E91Q58566643-4E2D6BE8-E501-46F7-9534-AD2E3B3B98BA
P2860
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anagliptin in the treatment of ...... cy, and patient acceptability.
@en
type
label
Anagliptin in the treatment of ...... cy, and patient acceptability.
@en
prefLabel
Anagliptin in the treatment of ...... cy, and patient acceptability.
@en
P2860
P356
P1476
Anagliptin in the treatment of ...... acy, and patient acceptability
@en
P2093
Mariko Abe
Shinya Nishio
P2860
P304
P356
10.2147/DMSO.S54679
P50
P577
2015-03-18T00:00:00Z